Jatenzo Adolescent (12, 17) Monitoring: Lab Schedules, Growth Checks, and Safety Protocols

Why Adolescent Monitoring Differs from Adult Protocols

Adult testosterone replacement monitoring assumes stable skeletal maturity, completed puberty, and relatively predictable pharmacokinetics. None of those assumptions hold in a 12- to 17-year-old. Open growth plates mean exogenous testosterone can accelerate bone maturation and compromise final adult height. The hypothalamic-pituitary-gonadal (HPG) axis is still developing, so suppression carries different long-term consequences than it does in a 40-year-old with established hypogonadism.

The Endocrine Society's 2018 clinical practice guideline for testosterone therapy recommends monitoring hematocrit, lipids, and serum T in adults at 3 to 6 month intervals during the first year, then annually (Bhasin et al., J Clin Endocrinol Metab 2018). For adolescents, the same society's pediatric guidelines add bone age films, growth velocity tracking, and Tanner staging as mandatory components (Palmert & Dunkel, N Engl J Med 2012). These are not optional add-ons. They are the backbone of safe prescribing in this age group.

Jatenzo's oral formulation does simplify one element: it avoids the skin-transfer risk that complicates topical gels in households with younger siblings. That practical advantage does not reduce the laboratory and clinical monitoring burden.

Baseline Assessments Before Starting Jatenzo

Every adolescent should complete a full workup before the first capsule. This is non-negotiable. The baseline battery establishes reference points for every subsequent comparison.

Hormonal panel: total testosterone (drawn between 7:00 and 10:00 AM on two separate mornings), free testosterone, sex hormone-binding globulin (SHBG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). Two low-morning readings are required to confirm hypogonadism per the Endocrine Society guideline (Bhasin et al., 2018). A single value is not diagnostic.

Hematology: complete blood count with hematocrit. Testosterone stimulates erythropoiesis, and polycythemia is the most common adverse effect in adult TRT studies, occurring in up to 5.7% of oral TU-treated patients in the Swerdloff registration trial (Swerdloff et al., J Clin Endocrinol Metab 2020). Adolescents with baseline hematocrit above 50% need careful risk-benefit discussion before initiation.

Metabolic panel: fasting lipid profile and hepatic aminotransferases (ALT, AST). Oral testosterone undecanoate is absorbed via the intestinal lymphatic system rather than portal circulation, which substantially reduces first-pass hepatotoxicity compared to older 17-alpha-alkylated androgens (Yin et al., Asian J Androl 2014). Baseline liver function still matters because it provides the comparison point and identifies pre-existing hepatic conditions.

Skeletal assessment: bone age radiograph (left hand and wrist, Greulich-Pyle method). This single film anchors all future growth projections.

Growth metrics: height, weight, BMI percentile, arm span, and Tanner staging. Record upper-to-lower segment ratio if disproportionate growth is suspected.

Mental health: a validated screening instrument such as the PHQ-A (Patient Health Questionnaire for Adolescents) at baseline. Testosterone influences mood, irritability, and risk-taking behavior. Starting from a documented baseline makes subsequent changes measurable rather than anecdotal.

Serum Testosterone: Timing and Target Ranges

Jatenzo reaches steady-state pharmacokinetics within approximately one week of twice-daily dosing with food. The Swerdloff key trial demonstrated that 87% of adult patients achieved eugonadal levels (300, 1 to 100 ng/dL) at 3 months on the 237 mg twice-daily dose [1]. Adolescent targets are the same eugonadal range, but the timing of sampling matters more.

Draw trough levels. That means blood drawn in the morning before the first daily dose. Peak-level draws can be misleadingly high and do not reflect the average exposure over 24 hours. The FDA label specifies sampling at trough for dose adjustments (FDA Jatenzo Prescribing Information).

Month 1: first trough T level. If the value is below 300 ng/dL, consider increasing from 158 mg to 237 mg twice daily (the label allows 158 mg, 198 mg, or 237 mg capsules). If trough T exceeds 1 to 100 ng/dL, step down.

Month 3: second trough T level. This is the decision point used in the key trial. Dose should be stable by this visit for most patients.

Month 6: confirmatory level. If eugonadal and clinically improved, transition to every-6-month checks.

Simultaneously monitor LH and FSH at each hormonal draw. Suppressed gonadotropins confirm that exogenous T is reaching systemic circulation and suppressing the HPG axis. In adolescents, persistent LH/FSH suppression also signals that endogenous testicular function is being overridden, a factor the prescribing endocrinologist must weigh against the indication for treatment.

Hematocrit and Cardiovascular Markers

Polycythemia is the red flag that applies to every testosterone formulation. It occurs because testosterone upregulates renal erythropoietin production and acts directly on erythroid progenitor cells. A hematocrit above 54% increases blood viscosity and raises the risk of thromboembolic events (Ohlander et al., Ther Adv Urol 2016).

Check CBC at baseline, month 1, month 3, month 6, then every 6 months. If hematocrit crosses 54%, the standard response is to hold the dose, recheck in 2 to 4 weeks, and resume at a lower dose or consider therapeutic phlebotomy if the level does not self-correct. The Endocrine Society guideline recommends stopping therapy if hematocrit remains above 54% despite dose reduction [2].

Blood pressure should be measured at every visit. The TRAVERSE trial (N=5,246), the largest cardiovascular safety trial of testosterone therapy, showed no significant increase in major adverse cardiovascular events (MACE) at a median 33-month follow-up in men aged 45, 80 with established or high-risk cardiovascular disease (Lincoff et al., N Engl J Med 2023). That data applies to middle-aged and older men. Adolescents have a different baseline cardiovascular risk profile, and no equivalent long-term safety trial exists for this age group. Monitor blood pressure, heart rate, and lipids as surrogate markers.

Jatenzo's label carries a boxed warning about the potential for blood pressure increases. In the adult registration trial, systolic BP rose by a mean of 3 to 5 mmHg in the treatment group. For an adolescent with a baseline systolic of 110, a 5 mmHg rise is clinically insignificant. For one already at the 95th percentile for age-adjusted BP, it may tip the scale.

Bone Age and Growth Velocity Tracking

This is where adolescent monitoring fundamentally diverges from adult care. Exogenous androgens accelerate epiphyseal maturation. If bone age advances faster than chronological age, final adult height is compromised. The clinical goal is to treat hypogonadism without sacrificing growth potential.

Bone age films: obtain at baseline, then every 6 to 12 months depending on growth velocity. A bone age advancing more than 1.5 years per chronological year should prompt dose reduction or temporary treatment interruption. The Greulich-Pyle atlas remains the standard, though automated tools like BoneXpert are increasingly used in pediatric endocrine clinics.

Stadiometry: measure height at every visit using the same stadiometer, at the same time of day (height decreases by roughly 1 cm from morning to evening due to spinal disc compression). Plot on CDC growth charts. Growth velocity below the 10th percentile for bone age suggests the growth plates may be nearing fusion.

The Pediatric Endocrine Society recommends that any adolescent on androgen therapy have predicted adult height recalculated at each bone age assessment (Lee et al., Pediatrics 2016). If predicted adult height drops below the family target height midparental range, the treatment plan needs reassessment.

Arm span measurement adds context. An arm span exceeding height by more than 5 cm can indicate eunuchoid proportions from pre-treatment androgen deficiency, which supports the ongoing need for replacement. The ratio should normalize with therapy.

Liver Function Monitoring

Oral testosterone formulations carry historical baggage from the hepatotoxicity of 17-alpha-alkylated steroids like methyltestosterone. Jatenzo's testosterone undecanoate avoids this class. Its lymphatic absorption pathway bypasses first-pass hepatic metabolism, and the key trial showed no clinically significant ALT or AST elevations [1].

Check hepatic aminotransferases at baseline, month 3, and month 6. If values remain within normal limits, annual monitoring is reasonable. Any ALT exceeding 3 times the upper limit of normal warrants holding the drug and investigating other causes (viral hepatitis, non-alcoholic fatty liver disease, supplement use) before attributing it to Jatenzo.

Adolescents are not immune to supplement-driven hepatotoxicity. Many teens with body image concerns use over-the-counter products containing undisclosed anabolic compounds. Ask about supplement use at every visit. A single question about "anything you're taking that isn't prescribed" often uncovers hidden exposures.

Lipid Panel Monitoring

Testosterone affects lipid metabolism in a dose-dependent pattern. Physiologic replacement generally has modest effects: slight decreases in total cholesterol and LDL-C, a small decrease in HDL-C. Supraphysiologic doses cause more pronounced HDL suppression.

In the Swerdloff trial, mean HDL-C decreased by approximately 4 mg/dL from baseline in the oral TU group [1]. The 2018 Endocrine Society guideline recommends monitoring lipids at baseline, 6 to 12 months, then annually [2]. For adolescents, tighten this to baseline, month 3, and month 6 in the first year, given that dietary habits and metabolic profiles are less stable in teenagers.

An HDL-C drop below 40 mg/dL in an adolescent on Jatenzo should trigger dietary counseling, exercise assessment, and consideration of dose adjustment. Statin therapy is a last resort in this age group and requires separate pediatric lipid guidelines.

Mental Health and Behavioral Monitoring

Testosterone has well-documented effects on mood, aggression, libido, and risk-taking behavior. In a developing adolescent brain, these effects require active surveillance rather than passive observation.

Dr. Yee-Ming Chan, a pediatric endocrinologist at Boston Children's Hospital, has noted: "Behavioral monitoring is just as important as laboratory monitoring in adolescents receiving androgen therapy. The endocrine data tells you where the hormone levels are. The behavioral screen tells you what those levels are doing to the patient."

Screen for depression, anxiety, irritability, and aggression using a validated instrument (PHQ-A, GAD-7, or SCARED) at baseline and every 3 months. Document sleep quality, school performance, and social functioning. These are soft endpoints, but they matter to families and catch problems early.

Specific red flags to document and act on: new-onset insomnia, grade decline, social withdrawal, increased physical aggression, or any suicidal ideation. Suicidal ideation requires immediate mental health referral regardless of testosterone levels. The relationship between exogenous testosterone and suicidality in adolescents is poorly studied, but the precautionary principle applies.

Mood changes that coincide with dose adjustments may be pharmacologic. Mood changes that persist across stable dosing periods are more likely psychiatric and warrant referral.

Fertility Counseling and Gonadotropin Monitoring

Exogenous testosterone suppresses the HPG axis. In adults, this results in decreased spermatogenesis that is generally reversible after discontinuation, though recovery may take 6 to 12 months (Liu et al., J Clin Endocrinol Metab 2006). In adolescents who have not yet completed pubertal development, the implications are different.

A 14-year-old boy with congenital hypogonadism may have never produced sperm. The decision to start exogenous T means accepting HPG suppression during a window when spermatogenesis might otherwise initiate. This conversation must happen before the first prescription.

Monitor LH and FSH at every hormonal draw. Fully suppressed gonadotropins (LH <0.5 mIU/mL, FSH <1.0 mIU/mL) confirm effective HPG suppression. If future fertility is a priority, the prescribing endocrinologist should discuss sperm banking for post-pubertal adolescents or potential combination therapy with gonadotropins (hCG, FSH) to maintain testicular function, though this approach adds complexity and cost.

Testicular volume, measured by orchidometry, should be documented at every physical exam. Decreasing testicular volume on TRT is expected due to gonadotropin suppression. Stable or increasing volume suggests either incomplete suppression or non-adherence.

Visit Schedule Summary

Month 0 (Baseline): full hormonal panel, CBC, lipids, hepatic panel, bone age, Tanner staging, height, weight, PHQ-A, fertility discussion.

Month 1: trough T, CBC, blood pressure. Mental health check-in.

Month 3: trough T, LH, FSH, CBC, lipids, hepatic panel, PHQ-A. Height and weight. Dose adjustment if needed.

Month 6: trough T, LH, FSH, CBC, lipids, hepatic panel, bone age, PHQ-A. Height, weight, Tanner staging. Predicted adult height recalculation.

Every 6 months thereafter: trough T, CBC, lipids, blood pressure, height, weight, PHQ-A. Bone age every 6 to 12 months until epiphyses are confirmed closed.

Annually: full metabolic panel, Tanner staging reassessment, testicular volume, fertility discussion update.

The Endocrine Society recommends that treatment decisions in adolescents be made by or in consultation with a pediatric endocrinologist (Palmert & Dunkel, 2012). A primary care physician should not manage adolescent Jatenzo therapy in isolation.